Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like "Trap" in Participants With Neovascular Age-Related Macular Degeneration With or Without Geographic Atrophy - STAT Study

NCT07520318 is registered in ClinicalTrials.gov with Shenzhen Oculgen Biomedical Technology Co., Ltd. as lead sponsor.

NCT NCT07520318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07520318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like "Trap" in Participants With Neovascular Age-Related Macular Degeneration With or Without Geographic Atrophy - STAT Study
Lead sponsor
Shenzhen Oculgen Biomedical Technology Co., Ltd.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
April 17, 2026
Completion date
March 29, 2029
Enrollment
255 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adults with neovascular age-related macular degeneration